Back to News
Market Impact: 0.4
IDEAYA Biosciences, Inc. Reports Third Quarter 2026 Financial Results and Closes Phase 3 OptimUM-010 Trial
Source: Nasdaq
Healthcare & BiotechCorporate EarningsCompany Fundamentals
IDEAYA Biosciences reported Q3 2026 financial results and announced it would stop enrollment and close its Phase 3 OptimUM-010 trial. The provided article text cuts off after citing ongoing site activation and enrollment “c,” so it does not establish the full rationale or provide financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
IDYA-0.80
More News
- Truist cuts Ideaya Biosciences stock price target on revised estimates
- IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide